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ABSTRACT  30 
 31 
Background: There is little information about serum phosphate levels among patients with pulmonary 32 
tuberculosis (TB) and HIV infection.  33 
Objective: We aimed to to assess the role of TB, HIV, inflammation and other correlates of on serum phosphate 34 
levels.  35 
Methods: A cross-sectional study was conducted among TB patients and age- and sex-matched non-TB controls. 36 
Pulmonary TB patients were categorized as sputum- negative (TB-) and -positive (TB+), based on culture. Age- 37 
and sex-matched non-TB controls were randomly selected among neighbors to TB+ sputum-positive TB patients. 38 
Data on age, sex, alcohol and smoking habits were obtained. HIV status, serum phosphate, and the acute phase 39 
reactants C-reactive protein (serum CRP) and α1-acid glycoprotein (serum AGP) were determined. Linear 40 
regression analysis was used to identify correlates of serum phosphate.  41 
Results: Of 1605 participants, 355 (22.1%) were controls and 1250 (77.9%) TB patients, of which 9.9% and 42 
50.4% were HIV-infected. Serum phosphate was determined before start of TB treatment in 44%, and 1-14 days 43 
after start of treatment in 56%. Serum phosphate was up to 0.10 mmol/L higher 1-3 days after start of TB 44 
treatment, and lowest 4 days after treatment, after which it increased. In multivariable analysis, TB patients had 45 
0.09 (95%CI: 0.05; 0.13) mmol/L higher serum phosphate than controls, and those with HIV had 0.05 (95%CI: 46 
0.01; 0.08) mmol/L higher levels than those without. Smoking was also a positive correlate of serum phosphate, 47 
whereas male sex and age were negative correlates.  48 
Conclusion: While HIV and TB are associated with higher serum phosphate, our data suggest that TB treatment is 49 
followed by transient reductions in serum phosphate, which may reflect hypophosphataemia in some patients.  50 
 51 
Key words: Serum phosphate, phosphorus, tuberculosis; HIV, acute phase response 52 
 53 
 54 
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  56 
INTRODUCTION  57 
Phosphorus is an essential mineral in the body, being , a structural component of DNA and RNA and of 58 
membranes, and important for metabolism and storage of energy (1). Phosphorus is likely to be a limiting nutrient 59 
among individuals in low-income settings, since the typical diet is low in animal-source foods and high in cereals 60 
(2). Although cereals,  including maize, have a high content of phosphorus in the form of phytic acid (, ie inositol 61 
hexaphosphate), it is largely unabsorbable (2,3).  62 
 63 
Data on phosphorus status are is scarce, even among low-income individuals where phosphorus deficiency is 64 
likely to be common. Although serum phosphate is known to be a poor marker of phosphorus status, it is the only 65 
available (3), and low values are related to various clinical conditions. For example, serum phosphate is measured 66 
to monitor patients at risk of refeeding hypophosphataemia, a potentially fatal condition that arises when high 67 
energy feeding is initiated in as phosphorus depleted individuals suddenly are fed high amounts of energy (4). As 68 
refeeding restores metabolism, it also leads to further intracellular phosphorus depletion, due to utilization of 69 
phosphorus for anabolic processes and storage of energy through phosphorylation of ADP to ATP. Such 70 
refeeding hypophosphatemia potentially results in multi-organ failure and death (5).  71 
 72 
Recently, there has been a renewed interest in serum phosphate in patients with HIV infection on antiretroviral 73 
treatment (ART). Tenofovir has been shown to cause renal tubular function abnormalities (6), which is a known 74 
cause of hypophosphataemia (7,8). Among HIV patients starting ART in Zambia, a case of acute 75 
hypophosphataemia was described (9), and low serum phosphate prior to ART was found to be a predictor of 76 
early mortality among those with low BMI (10,11). Fortification of a lipid-based nutritional supplement with 77 
vitamins and minerals reduced renal wasting of phosphate among malnourished Zambian patients starting ART 78 
(2). 79 
 80 
As part of a larger nutrition study, we obtained cross-sectional data on serum phosphate among pulmonary TB 81 
patients and age- and sex-matched neighbourhood controls, with an aim to assess the level of serum phosphate 82 
and the role of pulmonary TB, HIV, the acute phase response and other potential correlates.  83 
84 
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METHODOLOGY  85 
 86 
Ethics Statement 87 
Ethical permission was obtained from the Medical Research Coordinating committee of the National Institute for 88 
Medical Research in Tanzania, and consultative approval was given by The Danish Central Medical Ethics 89 
Committee. Written and oral information was presented to all eligible participants by the health staff before 90 
written informed consent was obtained. Written consent was obtained from parents/legal guardians of any 91 
participant under 18 years of age. 92 
 93 
Study setting and design 94 
A cross-sectional study was conducted from April 2006 to March 2009 in Mwanza City, Tanzania, among TB 95 
patients recruited for a large nutrition intervention study and non-TB controls. Mwanza City is at the shores of 96 
Lake Victoria. The harvest is from May to July, and the staple foods are maize, cassava, sweet potato, rice, and 97 
millet. Fish is the most common animal-source food. and sSmall fish are often eaten whole, . but only 25% eat 98 
them >4 days per week (12). 99 
 100 
Recruitment and management of TB patients 101 
The TB patients were recruited at the four TB clinics under the TB treatment services, coordinated by the 102 
National Tuberculosis and Leprosy Programme. If residents of Mwanza city, Both both smearsputum-positive 103 
(TB+) and smearsputum–negative (TB-) TB patients, based on culture, were enrolled in the study after giving 104 
informed consent if they were residents of Mwanza city.  Patients were excluded if pregnant, under the age of 15 105 
years or were suffering from with extra-pulmonary TB , pregnancy, age under 15 years, or a terminal illness were 106 
excluded. The diagnosis of TB followed the World Health Organization (WHO) guidelines (13) using the Ziehl–107 
Neelsen staining technique (14).  Briefly, all patients suspected of having TB were asked to bring three sputum 108 
samples for microscopy, and chest X-rays were done as appropriate. Patients were considered to be smearsputum-109 
positive, if two samples tested positive or one sample tested positive and a chest X-ray was suggestive of TB, and 110 
to be smearsputum-negative TB patients if all the samples were negative, but chest X-ray and clinical suspicion 111 
was suggestive of TB, and there was non-response to a course of broad-spectrum antibiotics. After diagnosis all 112 
patients were started on a standardized TB treatment for 6-8 months based on existing national guidelines (15,16). 113 
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Those found to be HIV-infected were referred for management based on national guidelines at the time of the 114 
study (17). At On the day TB treatment was started, the patients also started daily supplementation as part of two 115 
nutrition intervention trials. In the energy-protein trial, those found TB+sputum-positive  and HIV co-infected 116 
were randomized to receive one or six energy–protein biscuit bars daily (18). One of the biscuit bars given to the 117 
experimental group and the one given to the control group contained additional micronutrients, so that the 118 
micronutrient intake was similar in the two groups. All other TB patients were randomized to a daily biscuit bar 119 
with or without additional micronutrients (19). Each biscuit bar weighed 30 g and contained 4·5 g protein, 615 kJ 120 
energy, and 120 mg P. 121 
  122 
Recruitment of non-TB controls 123 
400 Four hundred  consecutive smearsputum-positive participants were considered index cases for selection of 124 
age- and sex-matched neighbourhood non-TB controls. Mwanza City is divided into wards, streets and communal 125 
cells. Each cell has 10-20 households, and is headed by a ten- cell -leader. Each of the index patients was asked to 126 
provide his/her residential address and the name of his/her ten-cell leader. Using this information, the study team 127 
requested the ten-cell leader to provide the complete list of individuals in his/her jurisdiction meeting the age and 128 
sex recruitment criteria. Of these, one was randomly selected using a lottery method and invited to participate in 129 
the study as a non-TB control if meeting the following criteria: no history of previous TB exposure, active TB or 130 
TB treatment, no evidence of current active TB (cough, intermittent fevers, and excessive night sweating in the 131 
past two weeks and unexplained weight loss in the past month), same sex as index case, aged 15 years or above 132 
and age difference from index case less than five years, had lived in the same street as index case for at least three 133 
months, not pregnant, and consenting to participate in the study. Persons who were terminally ill were not invited. 134 
The recruitment of non-TB controls was done in parallel with inclusion of cases from October 2006 to January 135 
2009. 136 
 137 
Data collection 138 
For the purpose of the study, all TB patients provided an additional sputum sample for culture at the Zonal TB 139 
Reference Laboratory, and were subsequently categorized as TBsputum+ -positive or TBsputum-negative, based 140 
on culture. For missing or contaminated culture samples, the initial evaluation from sputum smear microscopy 141 
was used. All TB patients and controls had data on demography, smoking, and alcohol intake collected using 142 
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questionnaires, while data on ART were was retrieved from ART-use databases in ART clinics. Morning venous 143 
blood was collected in a 10 ml plain vacutainer tube for HIV testing and a 5 ml EDTA vacutainer tube for CD4 144 
count. This was preferably done immediately prior to start of TB treatment, but could for logistical reasons be 145 
delayed; median delay was . As previously reported, the median (range) delay of blood sampling was 1 (range 0–146 
14) days after initiation of TB treatment (20). All tubes were cooled on dry ice before transported to the 147 
laboratory, where they were centrifuged and serum samples were stored at -80◦C. HIV status was determined 148 
using Capillus HIV-1/HIV-2 (Trinity Biotech Plc., Wicklow, Ireland) and Determine HIV-1/HIV-2 (Inverness 149 
Medical Innovations, Inc., Delaware, U.S.A.) tests in parallel. HIV infection was diagnosed if both tests gave a 150 
positive result and HIV negative diagnosis was made if both tests produced a negative result. Indeterminate 151 
results were resolved using ELISA– Organon Uniform II (Organon Teknia Ltd, Boxtel, Netherlands). CD4 count 152 
was determined as cells/µl using a Partec Cyflow Counter (Partec GmbH, Münster, Germany). The biochemical 153 
analyses, ie acute phase reactants and phosphate, were conducted at Aalborg University Hospital, FBE Clinical 154 
Biochemistry South. Serum phosphate was determined using Phosphate (Inorganic) ver.2 (PHOS2) on a Cobas 155 
6000 instrument from Roche (Roche Diagnostics GmbH, Mannheim, Germany) according to the manufacturer’s 156 
instructions. The cut-offs used to define low and high serum phosphate were 0.80 and 1.60 mmol/L (3). Serum α1-157 
acid glycoprotein (AGP) was determined with a standard Alpha1-Acid Glycoprotein Kit using Beckman Coulter 158 
ImageH Immunochemistry Systems (Beckman Coulter, Galway, Ireland) and C-reactive protein (CRP) was 159 
determined with Tina-quant C-Reactive Protein Gen.3 (CRPL3) on a Roche COBAS 6000 instrument (Roche 160 
Diagnostics GmbH, Mannheim, Germany). 161 
 162 
Statistical analysis 163 
Normal probability plots were used to assess the distribution of continuous variables. Chi-square test was used to 164 
test for differences in proportions. To assess and adjust for the effect of TB treatment and nutritional interventions 165 
on serum phosphate in case blood sampling was delayed, a variable was created to express the number of days 166 
delay after start of TB treatment. For controls and those treated the same day or the day after blood sampling this 167 
variable was given the value 0. The two-sample t test or oneway ANOVA were used to test for differences in 168 
means between two or more groups, respectively, and Scheffe post hoc tests were used to adjust for multiple 169 
comparisons. Linear regression analysis was used to identify correlates of serum phosphate. The variables 170 
assessed were age, sex, smoking, consumption of alcohol, TB and HIV status, and serum CRP or AGP. Age and 171 
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sex, and variables found significant in the univariate analyses were assessed in a final multivariable analysis, with 172 
all variables included, with and without adjustment for elevated levels of either serum CRP or AGP. Year and 173 
month of recruitment and delay in blood sampling since initiation of TB treatment were adjusted for. We 174 
examined normal and residual-vs.-fitted plots to assess normality and homoscedasticity of residuals. Stata version 175 
12.1 (StataCorp, Texas, USA) was used for all analyses. 176 
177 
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RESULTS 178 
Of the 1605 study participants, 355 (22.1%) were controls and 1250 (77.9%) TB patients. Culture data were 179 
available on 1142 (91.4%) of the 1250 TB patients. In the remaining 108 (8.6%) cultures were 180 
contaminated or missing, and the categorization of TB patients as sputum-negative and sputum-positive 181 
therefore based on microscopy. Thus, of the 1250 TB patients, of which 427 (34.2%) were TBsputum-182 
negative and 823 (65.8%) TB+.  sputum-positive (Table 1). As previously reported (19), the HIV prevalence was 183 
higher among TB patients compared to controls (50.4 vs 9.9%, p<0.001), and higher among sputum-negativeTB- 184 
compared to TB+sputum-positive patients (64.4 vs 43.1%, p<0.001). The mean BMI was 18.8 among TB patients 185 
and 22.6 among controls (p<0.001). Data on serum phosphate were available for 1522 (94.8%) of the 1605 186 
participants. Among 349 controls, mean (±SD) serum phosphate was 1.14 (±0.28) mmol/L with 4.3% (n=15) 187 
having values below 0.80 mmol/L, and 4.9% (n=17) above 1.6 mmol/L, respectively. Among 1173 TB patients 188 
the mean (±SD) serum phosphate was 1.27 (±0.29) mmol/L, and 2.2% (n=26) had values below 0.80 mmol/L, and 189 
9.2% (n=108) above 1.6 mmol/L. Of these, 518 (44%) had blood samples taken before start of TB treatment, 190 
while 218 (18.6%) were bled with 1 day delay, and the remaining with 2-14 days delay. Those bled with delay 191 
were 2.3 (95% CI: 0.8; 3.7) years older, had a higher prevalence of HIV (54.7 vs 45.5%, p=0.01), whereas there 192 
was no difference in sex distribution (p>0.30).  As seen in the Figure 1, unadjusted mean serum phosphate was 193 
up to 0.10 mmol/L higher in those bled 1-3 days after start of TB treatment, and lowest in those bled with 4 days 194 
delay, after which it seemed to increase with number of days delay. Numbers were too small to allow 195 
stratification by nutritional intervention. 196 
 197 
Mean serum phosphate by category of sex, age, smoking, alcohol consumption, pulmonary TB and HIV is shown 198 
in Table 12, with TB patients and controls combined. There were no differences by sex and age in univariate 199 
analyses, but serum phosphate were higher in those smoking or taking alcohol. There was no difference in serum 200 
phosphate between TB-sputum-negative and TB+sputum-positive TB patients (1.26 vs 1.27 mmol/L, p=0.41). 201 
However, TB patients together had higher serum phosphate than controls (1.27 vs 1.14 mmol/L, p<0.0001). The 202 
difference was similar if tested only among the index cases and controls (1.26 vs 1.14 mmol/L, p<0.0001; not 203 
shown in table). HIV+ patients had higher serum phosphate than HIV- (1.29 vs 1.21 mmol/L, p<0.0001), 204 
irrespective of ART status. The association between HIV status and serum phosphate was not different between 205 
TB patients and controls (interaction, p=0.56, data not shown). While serum phosphate was higher among those 206 
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with HIV, it was lower in those with CD4 counts below 250 compared to above 500 cells/µL, although the 207 
difference was only marginally significant (p=0.08, Scheffe post-hoc). Elevated serum CRP or AGP were both 208 
associated with higher serum phosphate.  209 
 210 
The results of a multivariable analysis, with adjustment for year and months of recruitment and delay in blood 211 
sampling, are shown in Table 23. The relationship between age, sex, HIV, smoking and serum phosphate were 212 
not different between TB patients and controls (interaction, p>0.10). Without adjustment for elevated serum AGP 213 
(model 1), serum phosphate was lower in males compared to females, and lower in those above 25 years of age. 214 
Alcohol intake was not associated with serum phosphate, but current smoking was associated with higher levels. 215 
TB patients had 0.09 (95% CI: 0.05; 0.13) mmol/L higher serum phosphate compared to the non-TB controls, 216 
whereas there was no difference between sputum-positiveTB+ and TB-sputum-negative patients. Finally, those 217 
with HIV infection had 0.05 (95% CI: 0.01; 0.08) mmol/L higher levels than those without. The associations with 218 
delayed bleeding, assessed in this multivariable model, was similar to what was shown in the Figure 1. As such, 219 
delays for 1 to 3 days were associated with 0.10 (95% CI: 0.06; 0.15), 0.01 (95% CI: -0.06; 0.09) and 0.08 (95% 220 
CI: 0.02; 014) higher serum phosphate, while delay to day 4 was associated with 0.06 (95% CI: -0.01; 0.13) lower 221 
serum phosphate. If days since TB treatment were not adjusted for, then the regression coefficient for TB was 222 
0.12 (95% CI: 0.08; 0.15). 223 
 224 
Elevated serum AGP was a strong positive correlate of serum phosphate, while elevated serum CRP was not, in 225 
multivariable analysis. Adjustment for elevated serum AGP (Table 23, model 2) considerably reduced the 226 
regression coefficient of TB+sputum-positive TB (from 0.09 to 0.03 mmol/L), whereas that of HIV and other 227 
correlates did not change considerably. Compared to the overall mean serum phosphate of 1.24 (95% CI: 1.23; 228 
1.25), the intercept was 1.20 (95% CI: 1.13; 1.26), and reflects the mean among individuals in all reference 229 
categories, ie young, non-smoking females without TB, HIV and elevated serum AGP. While no interaction 230 
between age and sex was found (p=0.40), there was an interaction between age and sex among controls (p=0.01). 231 
The interaction reflected a decline in serum phosphate per 10 year increase in age among males (-0.04, 95%CI: -232 
0.08; -0.010, p=0.01), but not among females (0.01, 95%CI: -0.03; .05, p=0.56).  233 
234 
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DISCUSSION  235 
 236 
Hypophosphataemia 237 
We found that serum phosphate, compared to those examined before TB treatment start, was higher in those 238 
examined 1-3 days after start of TB treatment, but lower in those examined 4 days after. While selection bias 239 
cannot be excluded, this pattern more likely reflects changes in phosphate metabolism due to the commencement 240 
of TB treatment with regain in appetite, and increased food intake, from the diet as well as from the supplements 241 
provided as part of the trials. The nadir at day 4 may reflect that some TB patients could have refeeding 242 
hypophosphataemia. In the classical description of refeeding syndrome, starved individuals refed with high 243 
amounts of glucose and amino acids developed hypophosphataemia accompanied by cardio-pulmonary failure. 244 
The existence of a similar syndrome among HIV patients starting ART has been suggested (9–11), whereas it 245 
does not seem to have been studied among TB patients. Nevertheless, the risk and magnitude of refeeding 246 
hypophosphataemia after initiation of TB-treatment may depend on the initial phosphorus status, as well as the 247 
intake of energy and bioavailable phosphorus and other bulk minerals and probably vitamins. There is currently 248 
increasing awareness that patients with TB need nutritional care and support (21), and it is important to ensure 249 
adequate intake of phosphorus to not only to prevent refeeding syndrome, but also to support regain in lean mass 250 
and body functions. 251 
 252 
After adjustment for the effect of delayed blood sampling, TB was associated with 0.09 mmol/L higher serum 253 
phosphate, compared to no TB, much of which was explained by elevated serum acute phase reactants. Yet, there 254 
are several reasons to believe that phosphorus status was low. First, the staple food is maize and the intake of 255 
animal source foods is limited. This is supported by a relatively low mean serum phosphate among controls (1.14 256 
mmol/L), although within the reference interval was 0.80 and 1.60 mmol/L, with 4.3% having low values. 257 
Second, the TB patients in the study had typically been ill for some time, and we have previously shown that they 258 
have an average weight deficit of 9 kg (22). The weight deficit is due to lower habitual weight as well as reduced 259 
food intake and increased utilization of energy as a result of the TB disease itself. Since inflammation-induced 260 
wasting to a large extent is due to catabolism of lean mass, this may result in increased serum phosphate. It has 261 
been shown in children with inflammatory bowel disease, another condition involving systemic inflammation, 262 
that flare-up leads to a sustained upregulation (reduced degradation) of the phosphatonin Fibroblast Growth 263 
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Factor 23 (FBG23), which increases renal phosphorus excretion (23). Hence, although speculative, it is likely that 264 
patients with TB, despite the elevated serum phosphate, are phosphorus depleted, and may continue to have high 265 
urinary phosphorus excretion for some time. This will contribute to increase the phosphorus requirements during 266 
the critical period of convalescence when there is a need to rebuild lean mass, ie organ and muscle. 267 
 268 
HIV infection 269 
We found 0.05 mmol/L higher serum phosphate in those with compared to without HIV infection, both among 270 
TB patients and controls. Among HIV patients, serum phosphate was not different in the 76 ART-treated 271 
compared to the 558 ART-naïve patients. The main ART regimen used was stavudine/lamivudine/nevirapine, 272 
whereas tenofovir, known to cause hypophosphataemia as part of Fanconi’s syndrome (6,7), was not used.  In 273 
contrast to TB, only a minor part of the association between HIV and serum phosphate was explained by the acute 274 
phase response.  In a trial among malnourished Zambian and Tanzanian HIV patients starting ART, there were 275 
complex interrelationships between serum phosphate and early mortality which were accentuated by vitamin and 276 
mineral fortification of a lipid-based supplement (24,25)(Woodd et al., submitted for publication; Rehman et al., 277 
submitted for publication) although the supplement improved renal phosphate retention (2). The results suggested 278 
it was variability of serum phosphate, possibly due to poor metabolic control among malnourished, seriously ill 279 
patients, which was associated with mortality risk (25) (Rehman et al., submitted for publication).  280 
 281 
Serum phosphate was lower in males compared to females and in the higher compared to lower age groups in the 282 
multivariable models. However, among controls only, we found an interaction between age and sex, due to a 283 
decline in serum phosphate with increasing age in males, but not in females. The overall decline of serum 284 
phosphate with age has been reported from several population based studies (26,27). A large US study from the 285 
USA found a decline with age in men. However, in women, there was that the lack of a consistent a decline in 286 
serum phosphate with age among females concealed a decline up to 44 years as for males, and then a transient 287 
increase with the onset of menopause, in parallel with changes in tubular phosphate reabsorption (28). While this 288 
age-sex pattern was also seen among healthy adults in Tanzanians, it disappeared among TB patients, even after 289 
adjustment for other factors. The higher serum phosphate in smokers is also in accordance with previous studies 290 
(29), and may be explained by greater bone loss in smokers.  291 
Formatted: English (United States)
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 Despite the limitations of serum phosphate as a marker of phosphorus status, and of our cross-sectional 292 
design to draw conclusions about cause-effect relationship, the study suggests that some patients may experience 293 
refeeding hypophosphataemia a few days after start of treatment.   294 
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Table 1. Diagnosis of 1250 tuberculosis patients as sputum-negative or sputum-positive 
 Sputum status 
1  
 Positive 2  Negative 3 Total (%) 
Culture 754 4  388 1142 (91,4) 
Microscopy 69  39 108 (8,6) 
Total (%) 823 (65.8)  427 (34,2) 1250 (100%) 
1 Sputum status was based on culture, if available, otherwise microscopy.  
2 Patients were considered to have sputum-positive tuberculosis, if two samples tested positive or one 
sample tested positive and a chest X-ray was suggestive of tuberculosis. 
3 Patients were considered to have sputum-negative tuberculosis if all the samples were negative, but 
chest X-ray and clinical suspicion was suggestive of tuberculosis, and there was non-response to a course 
of broad-spectrum antibiotics. 
4 Based on 400 consecutive sputum-positive index cases 400 age- and sex-matched neighbourhood non-
TB controls were selected 
  295 
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 296 
Table 2. Serum phosphate (mmol/L) among 1173 of 1250 pulmonary TB patients and 349 of 355 non-
TB neighbourhood controls by categories of sex, age, smoking, pulmonary TB, HIV and serum acute 
phase reactants 1  
 % (n)  Mean (SD) 95% CI P 
Sex      
   Females 42.0 (639)  1.25 (0.28) 1.23; 1.28 0.11 
   Males 58.0 (883)  1.23 (0.31) 1.21; 1.25  
Age (y)      
   <25 21.9 (333)  1.27 (0.28) 1.23; 1.30 0.16 
   25-45 58.2 (886)  1.24 (0.30) 1.22; 1.25  
   45+ 19.9 (303)  1.23 (0.31) 1.19; 1.26  
Smoking      
   Never 71.3 (1073)  1.23 (0.30) 1.21; 1.25 0.04 
   Previously 8.9 (134)  1.27 (0.27) 1.22; 1.31  
   Currently 19.8 (297)  1.27 (0.28) 1.24; 1.30  
Alcohol intake      
   No 58.0 (883)  1.23 (0.29) 1.21; 1.24 0.03 
   Yes 42.0 (638)  1.26 (0.31)   
Pulmonary TB status 1      
   Non-TB control 22.9 (349)  1.14 (0.28) 1.11; 1.17 <0.0001 
   TB-Sputum-negative TB 26.7 (406)  1.26 (0.27) 1.23; 1.29  
   TB+Sputum-positive TB 50.4 (767)  1.27 (0.31) 1.25; 1.30  
HIV and ART status      
   HIV- 58.3 (888)  1.21 (0.26) 1.19; 1.22 <0.0001 
   HIV+ not on ART 36.7 (558)  1.29 (0.34) 1.26; 1.31  
   HIV+ on ART 5.0 (76)  1.28 (0.29) 1.22; 1.35  
CD4 count (cells/µL)      
   HIV-   58.4 (888)  1.21 (0.26)  <0.0001 
   500+ 6.4 (97)  1.35 (0.32) 1.28; 1.41  
   250-500 12.6 (191)  1.30 (0.31) 1.26; 1.34  
   <250 22.7 (345)  1.26 (0.35) 1.22; 1.30  
Serum C-Reactive Protein (mg/L)      
   ≤ 2 20.1 (305)  1.16 (0.28) 1.13; 1.20 <0.0001 
   2-10 13.3 (201)  1.19 (0.24) 1.15; 1.22  
   10-50 18.2 (275)  1.24 (0.26) 1.21; 1.27  
   50-100 25.7 (390)  1.26 (0.27) 1.23; 1.28  
   100+ 22.7 (344)  1.32 (0.36) 1.28; 1.35  
Serum α1-Acid Glycoprotein (mg/L)      
   ≤ 1 25.6 (389)  1.15 (0.27) 1.13; 1.18 <0.0001 
   1-2 20.1 (305)  1.22 (0.27) 1.19; 1.25  
   2-3 37.4 (567)  1.26 (0.26) 1.24; 1.28  
   3+ 16.9 (257)  1.35 (0.39) 1.30; 1.40  
1 Pulmonary TB status was based on culture, except where culture data were not available. For 355 
consecutively recruited sputum- positive TB patients a control was randomly selected among individuals 
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from the neighbourhood with same sex and age. Serum phosphate data were available on 1522, but n may 
sum up to less, due to missing data on smoking (n=18), alcohol intake (n=1), CD4 count (n=1), serum C-
Reactive Protein (n=7), serum α1-Acid Glycoprotein (n=4). P-values were based on t-test and oneway. 
TB is tuberculosis, HIV is human immunodeficiency syndrome, ART is antiretroviral treatment 
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Table 3. Multivariable models with correlates of serum phosphate in among 1173 of 1250 pulmonary TB 
patients and 349 of 355 non-TB neighbourhood controls with regression coefficient B, 95% confidence 
interval (CI) and P-values 1 
 Model 1 2  Model 2 3 
 B 95% CI P  B 95% CI P 
Sex        
   Female  -       
   Male  -0.04 -0.07; -0.005 0.02  -0.04 -0.07; -0.01 0.02 
Age (years)        
   <25  -       
   25-45  -0.06 -0.10; -0.03 0.001  -0.06 -0.10; -0.02 0.001 
   45+  -0.07 -0.12; -0.02 0.003  -0.06 -0.10; -0.01 0.02 
Smoking        
   Never -       
   Previously 0.04 -0.01; 0.10 0.12  0.04 -0.01; 0.10 0.13 
   Currently 0.06 0.02; 0.10 0.004  0.06 0.02; 0.10 0.004 
TB status 1        
   Non-TB control  -    -   
   TB 0.09 0.05; 0.13 
<0.000
1 
 0.03 -0.03; 0.09 0.34 
HIV status        
   HIV-  -       
   HIV+  0.05 0.01; 0.08 0.004  0.04 0.01; 0.07 0.02 
Serum α1-acid glycoprotein (mg/L)        
   <1      -   
   1-2      0.02 -0.04;0.08 0.56 
   2-3      0.05 -0.01; 11 0.10 
   3+      0.14 0.07; 0.20 <0.001 
1 Pulmonary TB status was based on culture, and microscopy only if culture data were not available. For 355 
consecutively recruited sputum positive TB patients a control was randomly selected among individuals with 
same sex and age from the neighbourhood. 2 Model 1: N=1491, adjusted R2=0.07 and intercept=1.20 (95% CI: 
1.14; 1.27). 3 Model 2: N=1487, adjusted R2=0.09 and intercept=1.20 (95% CI: 1.13; 1.26). Both models 
contained all the variables and were adjusted for year and months of recruitment and days since start of TB 
treatment. TB is tuberculosis, HIV is human immunodeficiency syndrome 
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Figure 1. Serum phosphate by day after start of of TB treatment. Based on linear regression, with 301 
adjustment for TB, and non-TB controls and TB patients commencing TB treatment before or at the day 302 
of blood sampling coded as 0. Number of participants: day 0 (n=867), 1 (n=218), 2 (n=72), 3 (n=102), 4 303 
(n=67), 5 (n=40), 6 (n=41) and 7-14 (n=115). 304 
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